Congratulations to Michael Honigberg, MD, MPP from Mass General Heart on receiving the Research Goes Red Grant from American Heart Association!

Read more: mgriblog.org/2022/10/13/mas… #womenshealth #hearthealth #research

What's the impact of empagliflozin on decongestion in acute heart failure? New insights from the EMPULSE trial in EHJ!

academic.oup.com/eurheartj/adva…

#SGLT2 #decongestion #heartfailure #empagliflozin #cardiotwitter European Society of Cardiology European Society of Cardiology Journals

Edward Fry President’s Address at #ACCLegConf citing work led by James Januzzi Jr MD re CV disease projections Hanna Gaggin Jason H. Wasfy, M.D. Cian McCarthy Nasrien E. Ibrahim, MD Malissa Wood Mass General Heart MGH Cardiology Fellows Massachusetts ACC Patrick Ellinor MGH Cardiovascular Research Center

Free PMC: Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography. pubmed.ncbi.nlm.nih.gov/35753356/

#Cardiology #angiography James Januzzi Jr MD Reza Mohebi

Regardless of achieved dose, #sacubitril /valsartan reduced cardiac biomarkers, improved health status, and significantly reversed cardiac remodeling processes in patients w/ #HFrEF . bit.ly/3TiYQ1s

#JACC #GDMTworks #HeartFailure #CardioTwitter Reza Mohebi James Januzzi Jr MD

The excellent 2022 #proCardioForum in Munchen was the brainchild of James Januzzi Jr MD, who could not join in person. The meeting ended on future innovations like liquid cardiac biopsies, digital decision tools & #brainheart connexions. Here Carolyn Lam hugs a virtual James Januzzi Jr MD.

A study co-authored by James Januzzi, MD, James Januzzi Jr MD was covered by MedPage Today. The study found that heart failure patients who took less than the target dose of Entresto still experienced health improvements. medpagetoday.com/cardiology/chf…

#ResearchLetter : In #HFrEF , treatment with sacubitril/valsartan was associated with reduction in mitral regurgitation severity. Data from the #PROVEHF study @JJHeart_doc Mass General Heart #AHAJournals ahajrnls.org/3CxLszQ

Wonderful to connect with old and new friends at #proCardioForum in Munich! Shelley Zieroth James Januzzi Jr MD Jasper Tromp Carolyn Lam Muthu Vaduganathan Faiez ZANNAD Emily Lau

Now out in JACC Journals, pleased to share our American College of Cardiology Expert Consensus Decision Pathway on the Evaluation of Acute Chest Pain in the ED led by Chair Mike kontos and Vice-Chair Dr. James De Lemos.

Link: jacc.org/doi/10.1016/j.…

Thread👇

1/

'For those unable to achieve maximum doses of Sac/Val, mechanistic benefits and improvement in health status may be expected, even at lower doses.' -James Januzzi Jr MD

These results are 'very encouraging,' said Minnow Walsh, MD, MACC: bit.ly/3fUeNgj @MedpageToday #CardioTwitter

The definition of a mentor--congratulations to Pradeep Natarajan on this well-deserved honor!

Reza Mohebi Javed Butler Michael Felker Jon Ward scottdavidsolomon Gregg Fonarow MD BiykemBozkurt Minnow Walsh, MD, MACC Clyde Yancy, MD, MSc Harriette Van Spall, MD MPH Mass General Research Institute Mass General Heart Baim Institute

Reza Mohebi Javed Butler Michael Felker Jon Ward scottdavidsolomon Gregg Fonarow MD BiykemBozkurt Minnow Walsh, MD, MACC Clyde Yancy, MD, MSc Harriette Van Spall, MD MPH

These results do not contradict clinical practice guidelines: therapies should be titrated to maximally tolerated doses when possible.
If it is not possible to reach target, it is reassuring to note mechanistic benefits are still seen even at low dose!

#GDMTworks